Alzamend Neuro (ALZN)
(Real Time Quote from BATS)
$2.21 USD
-0.17 (-7.14%)
Updated Aug 6, 2025 03:10 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALZN 2.21 -0.17(-7.14%)
Will ALZN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALZN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALZN
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?
ALZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ALZN
Alzamend Neuro (ALZN) to Present at Military Health Symposium
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium | ALZN Stock News
Alzamend Neuro to present at Military Health System Research Symposium
Alzamend Neuro (ALZN) Strengthens Financial Position with Strategic Achievements | ALZN Stock News
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs | ...